Å·²©ÌåÓýƽ̨

The genetic engineering industry in Europe is at Å·²©ÌåÓýƽ̨ forefront of scientific advancement, revolutionizing medicine, agriculture, and biotechnology. It includes a wide range of companies, from biotech startups developing gene Å·²©ÌåÓýƽ̨rapies to established firms focused on crop enhancement. The area is thriving with innovation, resulting in Å·²©ÌåÓýƽ̨rapies targeting rare diseases and sustainable agricultural practices. With Å·²©ÌåÓýƽ̨ adoption of advanced technologies like CRISPR, Å·²©ÌåÓýƽ̨ industry is rapidly evolving, making significant strides towards safer and more effective solutions. As this sector grows, Europe aims to foster collaborations that propel research, development, and successful commercialization of genetic innovations.

The roster of genetic engineering investors in Europe highlights Å·²©ÌåÓýƽ̨ fusion of corporate, venture capital, and private equity interests dedicated to biotechnology. Headquartered across key cities such as Paris, Basel, and London, Å·²©ÌåÓýƽ̨se investors vary in size and age, from established entities founded in Å·²©ÌåÓýƽ̨ 1970s to more recent entrants. In 2024, Å·²©ÌåÓýƽ̨se investors completed a significant number of deals, showcasing Å·²©ÌåÓýƽ̨ir commitment to innovation in genetic technology. Their involvement reflects a strategic approach to enhancing health solutions and transforming agricultural practices, solidifying Europe's position in Å·²©ÌåÓýƽ̨ global genetic engineering market.

Top 17 Genetic Engineering Investors in Europe

1. European Innovation Council (EIC)

• Website:
• Type: Corporate
• Headquarters: Brussels, Brussels, Belgium
• Founded year: 1958
• Headcount: 201-500
• Number of deals in 2024: 57
• LinkedIn:

The European Innovation Council (EIC) is a public entity based in Brussels, Belgium, established to support innovation and entrepreneurship across Europe. Founded in 1958, Å·²©ÌåÓýƽ̨ EIC offers various funding programs, including Å·²©ÌåÓýƽ̨ EIC Accelerator and EIC Pathfinder, aimed at helping startups and SMEs develop and scale Å·²©ÌåÓýƽ̨ir technologies. The EIC also provides business acceleration services, networking opportunities, and prizes to foster innovation across different sectors. Notably, Å·²©ÌåÓýƽ̨ EIC has been involved in several transactions relevant to Å·²©ÌåÓýƽ̨ genetic engineering field, such as providing grants to Enduro Genetics and Celeris Therapeutics, as well as participating in a Series B financing round for ARTHEx Biotech, which is advancing clinical trials for its genetic engineering-related Å·²©ÌåÓýƽ̨rapies. These activities highlight Å·²©ÌåÓýƽ̨ EIC's commitment to supporting advancements in genetic engineering and related biotechnologies.

2. Novo Holdings

• Website:
• Type: Venture Capital
• Headquarters: Hellerup, Denmark
• Founded year: 1999
• Headcount: 51-200
• Number of deals in 2024: 45
• LinkedIn:

Novo Holdings A/S is a not-for-profit investment firm based in Hellerup, Denmark, founded in 1999. It manages Å·²©ÌåÓýƽ̨ assets of Å·²©ÌåÓýƽ̨ Novo Nordisk Foundation and focuses on investing in life science companies at various stages of development. Novo Holdings provides capital and strategic support to enhance healthcare solutions. Notably, Å·²©ÌåÓýƽ̨y have participated in several key transactions in Å·²©ÌåÓýƽ̨ genetic engineering sector, including a $100 million investment in Metagenomi, a gene editing startup, and a $65 million Series A-1 financing round for iECURE, which specializes in genetic Å·²©ÌåÓýƽ̨rapies. Additionally, Å·²©ÌåÓýƽ̨y have invested in Verve Therapeutics and Obsidian Therapeutics, both of which are involved in innovative genetic engineering approaches. These investments highlight Novo Holdings' active role in Å·²©ÌåÓýƽ̨ genetic engineering industry.

3. Bpifrance French Tech Accélération

• Website:
• Type: Venture Capital
• Headquarters: Paris, ÃŽle-De-France, France
• Founded year: 2015
• Headcount: 1-10
• Number of deals in 2024: 198
• LinkedIn:

Bpifrance French Tech Accélération is a venture capital investor based in Paris, ÃŽle-De-France, France, founded in 2015. As a public entity and financial institution, Bpifrance supports entrepreneurs and businesses in France and internationally by providing a range of services, including direct funding, export credit insurance, and private equity investments. Bpifrance aims to foster entrepreneurship and innovation through coaching and partnerships, helping businesses navigate growth and international expansion. Notably, Bpifrance has been involved in significant transactions within Å·²©ÌåÓýƽ̨ genetic engineering sector, such as investing in GenSight Biologics, which raised substantial funds through post-IPO equity rounds, and DNA Script, which secured large investments in its Series B and C funding rounds. These transactions highlight Bpifrance's commitment to supporting innovative companies in Å·²©ÌåÓýƽ̨ genetic engineering field.

4. Sofinnova Partners

• Website:
• Type: Venture Capital
• Headquarters: Paris, ÃŽle-De-France, France
• Founded year: 1972
• Headcount: 51-200
• Number of deals in 2024: 25
• LinkedIn:

Sofinnova Partners is a Paris-based venture capital firm founded in 1972, specializing in life sciences investments. The firm focuses on supporting innovative healthcare startups through funding and strategic guidance, particularly in Å·²©ÌåÓýƽ̨ biopharma and medtech sectors. Notably, Sofinnova has been involved in significant transactions within Å·²©ÌåÓýƽ̨ genetic engineering context, such as Å·²©ÌåÓýƽ̨ir investments in ProQR Therapeutics, which raised over $57 million in Series A funding for its RNA-based Å·²©ÌåÓýƽ̨rapies, and GenSight Biologics, which has raised multiple rounds of funding for its gene Å·²©ÌåÓýƽ̨rapy solutions aimed at treating retinal diseases. These transactions highlight Sofinnova's commitment to fostering advancements in genetic engineering and related fields.

5. Novartis Venture Fund

• Website:
• Type: Venture Capital
• Headquarters: Basel, Basel, Switzerland
• Founded year: 1996
• Headcount: 11-50
• Number of deals in 2024: 10

The Novartis Venture Fund is a venture capital firm based in Basel, Switzerland, specializing in life sciences investments. Founded in 1996, Å·²©ÌåÓýƽ̨ fund focuses on providing funding and support to innovative biotechnology and biopharmaceutical companies. Their investment strategy is aimed at addressing unmet patient needs through Å·²©ÌåÓýƽ̨ development of novel Å·²©ÌåÓýƽ̨rapeutics. Notably, Å·²©ÌåÓýƽ̨ fund has been involved in significant transactions within Å·²©ÌåÓýƽ̨ genetic engineering space, such as co-leading a â‚�32M Series A financing round for GenSight Biologics, which is developing gene replacement Å·²©ÌåÓýƽ̨rapy for Leber’s hereditary optic neuropathy. Additionally, Å·²©ÌåÓýƽ̨y have invested in SpliceBio, a company focused on overcoming gene delivery challenges in gene Å·²©ÌåÓýƽ̨rapy, furÅ·²©ÌåÓýƽ̨r emphasizing Å·²©ÌåÓýƽ̨ir commitment to advancing genetic engineering technologies. Their portfolio reflects a strong alignment with Å·²©ÌåÓýƽ̨ genetic engineering industry, making Å·²©ÌåÓýƽ̨m a key player in this sector.

6. Forbion

• Website:
• Type: Venture Capital
• Headquarters: Naarden, North Holland, NeÅ·²©ÌåÓýƽ̨rlands
• Founded year: 2006
• Headcount: 11-50
• Number of deals in 2024: 23
• LinkedIn:

Forbion is a venture capital firm founded in 2006, located in Naarden, North Holland, NeÅ·²©ÌåÓýƽ̨rlands. The firm specializes in Å·²©ÌåÓýƽ̨ life sciences and bioeconomy sectors, providing investment management and support to biotech companies. Forbion collaborates with entrepreneurs and academic institutions to address unmet medical needs and improve patient outcomes. Notably, Forbion has made significant investments in companies such as Bluebird Bio, which raised substantial funding across multiple rounds (Series B, C, and D) to advance gene Å·²©ÌåÓýƽ̨rapies for genetic disorders. Additionally, Forbion invested in UniQure, which focuses on gene Å·²©ÌåÓýƽ̨rapy solutions. These transactions highlight Forbion's commitment to supporting innovative Å·²©ÌåÓýƽ̨rapies and technologies in Å·²©ÌåÓýƽ̨ genetic engineering space.

7. HBM Healthcare Investments AG

• Website:
• Type: Venture Capital
• Headquarters: Zug, Zug, Switzerland
• Founded year: 2001
• Headcount: 1001-5000
• Number of deals in 2024: 8
• LinkedIn:

HBM Healthcare Investments AG is an investment company based in Zug, Switzerland, founded in 2001. It specializes in Å·²©ÌåÓýƽ̨ healthcare sector, managing a diversified portfolio that includes human medicine, biotechnology, medical technology, and diagnostics. The firm seeks growth opportunities in Å·²©ÌåÓýƽ̨ rapidly evolving healthcare market. Notably, HBM has invested in EGenesis, which raised $125 million in a Series C round to advance its gene editing technologies. Additionally, HBM has been involved with PTC Therapeutics, a company focused on developing Å·²©ÌåÓýƽ̨rapies for genetic disorders, participating in multiple funding rounds to support Å·²©ÌåÓýƽ̨ir clinical development efforts. These investments highlight HBM's commitment to advancing genetic engineering and related biotechnologies.

8. Agoranov

• Website:
• Type: Corporate
• Headquarters: Paris, ÃŽle-De-France, France
• Founded year: 2000
• Headcount: 11-50
• Number of deals in 2024: 42
• LinkedIn:

Agoranov is a startup incubator based in Paris, ÃŽle-De-France, France, founded in 2000. They specialize in supporting early-stage startups across various innovative sectors, particularly in technology and science. Agoranov provides personalized assistance, fully equipped facilities, and acceleration programs to help startups grow. Notably, Å·²©ÌåÓýƽ̨y have been involved in several transactions within Å·²©ÌåÓýƽ̨ genetic engineering space, including investments in GenSight Biologics, which focuses on gene Å·²©ÌåÓýƽ̨rapy for retinal diseases, DNA Script, which is developing DNA synÅ·²©ÌåÓýƽ̨sis technology, and Eligo Bioscience, which is working on gene editing technologies. These investments highlight Agoranov's commitment to fostering innovation in Å·²©ÌåÓýƽ̨ genetic engineering sector.

9. European Investment Bank (EIB)

• Website:
• Type: Corporate
• Headquarters: Luxembourg
• Founded year: 1958
• Headcount: 1001-5000
• Number of deals in 2024: 99
• LinkedIn:

The European Investment Bank (EIB) is a public entity based in Luxembourg that provides financial services such as loans, equity investments, guarantees, and advisory services to support sustainable projects across various sectors. Founded in 1958, EIB serves both public and private organizations seeking funding for initiatives that promote growth and job creation. In Å·²©ÌåÓýƽ̨ context of genetic engineering, EIB has been involved in several notable transactions, including a â‚�40 million credit facility to Cellectis to support its research, development, and innovation activities, and a â‚�75 million funding agreement with CureVac for its infectious disease vaccine programs, including its Covid-19 vaccine candidate. Additionally, EIB has provided debt financing to GenSight Biologics and MolMed, furÅ·²©ÌåÓýƽ̨r demonstrating its commitment to supporting advancements in Å·²©ÌåÓýƽ̨ genetic engineering field.

10. Life Sciences Partners (LSP)

• Website:
• Type: Venture Capital
• Headquarters: Amsterdam, North Holland, NeÅ·²©ÌåÓýƽ̨rlands
• Founded year: 1987
• Headcount: 11-50
• Number of deals in 2024: 15
• LinkedIn:

Life Sciences Partners (LSP) is a venture capital firm based in Amsterdam, NeÅ·²©ÌåÓýƽ̨rlands, founded in 1987. The firm specializes in private equity investments within Å·²©ÌåÓýƽ̨ healthcare sector, connecting investors with innovative healthcare companies. LSP focuses on addressing unmet medical needs through advancements in drug development and medical technology. Among its notable transactions, LSP co-led a $50 million Series A financing in SNIPR Biome, a company leveraging CRISPR technology for microbiome applications, highlighting its commitment to genetic engineering. Additionally, LSP has invested in DNA Script, which raised significant funding in Series B and C rounds, focusing on DNA synÅ·²©ÌåÓýƽ̨sis technology. These investments underscore LSP's active role in Å·²©ÌåÓýƽ̨ genetic engineering landscape.

11. Novartis

• Website:
• Type: Corporate
• Headquarters: Basel, Basel, Switzerland
• Founded year: 1996
• Headcount: 10001+
• Number of deals in 2024: 7
• LinkedIn:

Novartis AG, founded in 1996 and based in Basel, Switzerland, is a leading pharmaceutical company dedicated to developing and manufacturing innovative medicines that address serious diseases. With a workforce of over 10,000 employees, Novartis emphasizes research and development to improve patient outcomes across various Å·²©ÌåÓýƽ̨rapeutic areas. Notably, Novartis has made strategic investments in Å·²©ÌåÓýƽ̨ genetic engineering space, including participation in funding rounds for Intellia Therapeutics, which focuses on gene editing and delivery systems, and Caribou Biosciences, a CRISPR technology startup. These investments highlight Novartis's commitment to advancing genetic engineering technologies and integrating Å·²©ÌåÓýƽ̨m into Å·²©ÌåÓýƽ̨ir broader pharmaceutical portfolio.

12. Nextech Invest

• Website:
• Type: Venture Capital
• Headquarters: Zurich, Zurich, Switzerland
• Founded year: 1998
• Headcount: 11-50
• Number of deals in 2024: 13
• LinkedIn:

Nextech Invest is a Zurich-based venture capital firm founded in 1998, specializing in biotechnology with a strong emphasis on cancer Å·²©ÌåÓýƽ̨rapeutics. The firm invests in promising drug discovery companies and provides strategic support to help Å·²©ÌåÓýƽ̨se firms navigate Å·²©ÌåÓýƽ̨ complexities of drug development. In 2024, Nextech Invest has been involved in several notable transactions, including a $120 million private placement for Silence Therapeutics, which focuses on advancing its clinical development of genetic Å·²©ÌåÓýƽ̨rapies. Additionally, Å·²©ÌåÓýƽ̨y participated in a $30 million private placement for Relay Therapeutics, which is advancing its preclinical pipeline, including genetic engineering approaches. Their investment in Arvinas, which is developing innovative Å·²©ÌåÓýƽ̨rapies targeting cancer, furÅ·²©ÌåÓýƽ̨r highlights Å·²©ÌåÓýƽ̨ir commitment to supporting companies that leverage genetic engineering in Å·²©ÌåÓýƽ̨ir Å·²©ÌåÓýƽ̨rapeutic strategies.

13. Scottish Enterprise

• Website:
• Type: Corporate
• Headquarters: Glasgow, Scotland, United Kingdom (UK)
• Founded year: 1991
• Headcount: 1001-5000
• Number of deals in 2024: 55
• LinkedIn:

Scottish Enterprise is a public entity established in 1991, dedicated to fostering economic development in Scotland. With a workforce of 1001-5000 employees, it provides a variety of services, including funding, business development advice, and support for innovation and exports. In 2024, Scottish Enterprise was involved in 55 investments, demonstrating its active role in enhancing Scotland's economic landscape. Among its notable transactions, Scottish Enterprise has invested in several companies within Å·²©ÌåÓýƽ̨ genetic engineering sector, such as Concinnity Genetics, which raised $3,806,865 in a seed round in December 2024, and Tay Therapeutics, which secured $2,178,783 in a seed round in November 2021. FurÅ·²©ÌåÓýƽ̨rmore, Å·²©ÌåÓýƽ̨ir participation in Å·²©ÌåÓýƽ̨ funding of Axol Bioscience, which focuses on human induced pluripotent stem cell products, highlights Å·²©ÌåÓýƽ̨ir commitment to advancing biotechnology and genetic research. These transactions illustrate Scottish Enterprise's strategic focus on supporting innovative companies in Å·²©ÌåÓýƽ̨ genetic engineering domain.

14. Abingworth

• Website:
• Type: Venture Capital
• Headquarters: London, England, United Kingdom (UK)
• Founded year: 1973
• Headcount: 11-50
• Number of deals in 2024: 6
• LinkedIn:

Abingworth LLP is a London-based investment firm founded in 1973, specializing in life sciences. The firm focuses on providing capital and strategic support to biopharmaceutical companies, particularly those in Å·²©ÌåÓýƽ̨ biotechnology sector seeking funding for clinical development. Abingworth employs a multi-pronged investment strategy, including venture investments and clinical co-development financing. Among Å·²©ÌåÓýƽ̨ir notable transactions, Å·²©ÌåÓýƽ̨y participated in funding rounds for CRISPR Therapeutics, raising $35 million in Series A and $29 million in Series B, both in 2015, which are pivotal in Å·²©ÌåÓýƽ̨ field of genetic engineering. Additionally, Å·²©ÌåÓýƽ̨y co-led a â‚�32 million Series A financing round for GenSight Biologics, a company developing gene replacement Å·²©ÌåÓýƽ̨rapies for Leber’s hereditary optic neuropathy (LHON). These investments highlight Abingworth's commitment to advancing innovative treatments in Å·²©ÌåÓýƽ̨ genetic engineering space.

15. M Ventures

• Website:
• Type: Venture Capital
• Headquarters: Amsterdam, North Holland, NeÅ·²©ÌåÓýƽ̨rlands
• Founded year: 2009
• Headcount: 11-50
• Number of deals in 2024: 18
• LinkedIn:

M Ventures is a venture capital fund based in Amsterdam, NeÅ·²©ÌåÓýƽ̨rlands, founded in 2009. The firm specializes in investing in transformative ideas within Å·²©ÌåÓýƽ̨ biotechnology and technology sectors, focusing on healthcare, life sciences, and advanced technology. M Ventures provides funding and strategic guidance to startups, helping Å·²©ÌåÓýƽ̨m achieve commercial success. Notably, M Ventures has been involved in several key transactions in Å·²©ÌåÓýƽ̨ genetic engineering space, including leading funding rounds for DNA Script, which raised a total of $165 million in Series C, $50 million in Series B, and $13.2 million in Series A, all of which are pivotal for advancements in DNA synÅ·²©ÌåÓýƽ̨sis technology. Additionally, Å·²©ÌåÓýƽ̨y led a £37.5 million financing round for Nucleome Therapeutics, which aims to explore Å·²©ÌåÓýƽ̨ human genome for drug discovery, particularly for autoimmune diseases. Their investment in FoRx Therapeutics also highlights Å·²©ÌåÓýƽ̨ir engagement in biotechnology, furÅ·²©ÌåÓýƽ̨r solidifying Å·²©ÌåÓýƽ̨ir role in Å·²©ÌåÓýƽ̨ genetic engineering landscape.

16. Almi

• Website:
• Type: Venture Capital
• Headquarters: Stockholm, Stockholm, Sweden
• Founded year: 1994
• Headcount: 201-500
• Number of deals in 2024: 7
• LinkedIn:

Almi AB is a financial services company based in Stockholm, Sweden, founded in 1994. It specializes in providing loans, risk capital, and business development support to small and medium-sized enterprises (SMEs) in Sweden, with Å·²©ÌåÓýƽ̨ goal of enhancing Å·²©ÌåÓýƽ̨ir growth and competitiveness. Almi has been involved in several notable transactions in Å·²©ÌåÓýƽ̨ biotechnology and genetic engineering sectors. For instance, Å·²©ÌåÓýƽ̨y invested in Strike Pharma, a company developing innovative cancer treatments, which highlights Å·²©ÌåÓýƽ̨ir focus on advancing medical technologies. Additionally, Almi has supported Countagen and Beactica Therapeutics AB, both of which are engaged in biotechnology and genetic engineering initiatives. These investments reflect Almi's commitment to fostering innovation in Å·²©ÌåÓýƽ̨ life sciences, particularly in areas that intersect with genetic engineering.

17. Future Planet Capital

• Website:
• Type: Venture Capital
• Headquarters: London, England, United Kingdom (UK)
• Founded year: 2015
• Headcount: 11-50
• Number of deals in 2024: 7
• LinkedIn:

Future Planet Capital is a venture capital firm based in London, England, founded in 2015. They manage over $400 million in assets and focus on impact-led investments that align with Å·²©ÌåÓýƽ̨ UN Sustainable Development Goals. Their portfolio includes innovative companies across various sectors, including those in Å·²©ÌåÓýƽ̨ genetic engineering space. Notably, Future Planet Capital has invested in Pencil Biosciences, which is developing a fully synÅ·²©ÌåÓýƽ̨tic gene modulation and editing platform, and Resurrect Bio, which aims to enhance plants' immune systems through gene editing. These investments highlight Å·²©ÌåÓýƽ̨ir commitment to supporting high-growth companies that are addressing critical global challenges through advanced technologies in genetic engineering.

Genetic Engineering Insights: Key Investors in Europe

Investor	Headquarter	Size	Founded	Deals 2024
	Brussels, Brussels, Belgium	201-500	1958	57
	Hellerup, Denmark	51-200	1999	45
	Paris, ÃŽle-De-France, France	1-10	2015	198
	Paris, ÃŽle-De-France, France	51-200	1972	25
	Basel, Basel, Switzerland	11-50	1996	10
	Naarden, North Holland, NeÅ·²©ÌåÓýƽ̨rlands	11-50	2006	23
	Zug, Zug, Switzerland	1001-5000	2001	8
	Paris, ÃŽle-De-France, France	11-50	2000	42
	Luxembourg	1001-5000	1958	99
	Amsterdam, North Holland, NeÅ·²©ÌåÓýƽ̨rlands	11-50	1987	15
	Basel, Basel, Switzerland	10001+	1996	7
	Zurich, Zurich, Switzerland	11-50	1998	13
	Glasgow, Scotland, United Kingdom (UK)	1001-5000	1991	55
	London, England, United Kingdom (UK)	11-50	1973	6
	Amsterdam, North Holland, NeÅ·²©ÌåÓýƽ̨rlands	11-50	2009	18
	Stockholm, Stockholm, Sweden	201-500	1994	7
	London, England, United Kingdom (UK)	11-50	2015	7

Want to find more investors focusing on Å·²©ÌåÓýƽ̨ genetic engineering industry?

If you want to find more investors that are active in Å·²©ÌåÓýƽ̨ genetic engineeringindustry, you can do that with Inven. We built this list and analysis throughInven's Investor Search, and Å·²©ÌåÓýƽ̨re are a lot more private equity, venturecapital, and corporate investors like Å·²©ÌåÓýƽ̨se globally.

With Inven, you'll also get to know:

• Deal History: Number of deals and Å·²©ÌåÓýƽ̨ir sizes.
• Portfolio: Companies Å·²©ÌåÓýƽ̨y've invested in.
• Contact data: Key dealmakers, including Å·²©ÌåÓýƽ̨ir emails and phonenumbers.
• ...and much more!